4.5 Article

A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice

期刊

NEUROBIOLOGY OF AGING
卷 30, 期 9, 页码 1393-1405

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2007.11.022

关键词

Immunotherapy; Solubility; ABeta-peptide; Alzheimer's disease; Amyloid beta; Transgenic

资金

  1. Uppsala University
  2. Landstinget i Uppsala lan
  3. Swedish Brain Fund
  4. Bertil Hillstens Forskningsstiftelse
  5. Alzheimerfonden
  6. Sahlgrenska University Hospital
  7. Gamla Tjanarinnor
  8. Gun och Bertil Stolmes Stiftelse
  9. Magnus Bergvall
  10. Ahlonsstiftelsen
  11. Lars Hierta
  12. Lundstroms Minne
  13. Frimurarstiftelsen
  14. Svenska Lakarsallskapet
  15. Swedish Research Council [2006-2822, 2006-2818, 2006-6326, 2006-3464, 2004-2696]
  16. Knut and Alice Wallenberg foundation
  17. Swedish foundation for strategic research
  18. Sven and Ebba-Christina Hagbergs stiftelse

向作者/读者索取更多资源

Amyloid-beta (A beta) is a major drug target in Alzheimer's disease. Here, we demonstrate that deposited A beta is SDS insoluble in tgAPP-ArcSwe, a transgenic mouse model harboring the Arctic (E693G) and Swedish (KM670/671NL) APP mutations. Formic acid was needed to extract the majority of deposited A beta in both tgAPP-ArcSwe and Alzheimer's disease brain, but not in a commonly used type of mouse model with the Swedish mutation alone. Interestingly, the insoluble state of Arctic A beta was determined early on and did not gradually evolve with time. In tgAPP-AreSwe, A beta plaques displayed a patchy morphology with bundles of A beta fibrils, whereas amyloid cores in tgAPP-Swe were circular with radiating fibrils. Amyloid was more densely stacked in tgAPP-ArcSwe, as demonstrated with a conformation sensitive probe. A reduced increase in plasma A beta was observed following acute administration of an A beta antibody in tgAPP-ArcSwe, results that might imply reduced brain to plasma A beta efflux. TgAPP-ArcSwe, with its insoluble state of deposited A beta, could serve as a complementary model to better predict the outcome of clinical trials. (C) 2007 Elsevier Inc. All fights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据